Spectrum Pharmaceuticals Inc

Most Recent

  • uploads///Spectrum Pharmaceuticals Pipeline
    Company & Industry Overviews

    An Overview of Spectrum Pharmaceuticals’ Drug Pipeline

    Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.

    By Kenneth Smith
  • uploads///Folotyn
    Company & Industry Overviews

    Spectrum Pharmaceuticals’ Product Licensing Agreements

    In 2012, Spectrum Pharmaceuticals (SPPI) acquired the rights to market Zevalin outside the US from Bayer for 19 million euros.

    By Kenneth Smith
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///Spectrum net loss
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

    By Daniel Collins
  • uploads///headache _
    Company & Industry Overviews

    Why Spectrum Pharmaceuticals Stock Rose ~5% on September 6

    On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from the prior day’s close of $21.05.

    By Daniel Collins
  • uploads///Spectrum Pharmaceuticals Revenue Trend
    Company & Industry Overviews

    Chart in Focus: Spectrum Pharmaceuticals’ Financials

    In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.

    By Kenneth Smith
  • uploads///Marqibo Performance
    Company & Industry Overviews

    A Look at Spectrum Pharmaceuticals’ Recent Acquisitions

    Spectrum Pharmaceuticals (SPPI) acquired Talon Therapeutics in July 2013 for $11.3 million in cash and an issuance of 3.0 million shares.

    By Kenneth Smith
  • uploads///Analysts Ratings for Spectrum Pharmaceuticals
    Company & Industry Overviews

    Analysts’ Recommendations for Spectrum Pharmaceuticals

    Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Existing Chemotherapy Drugs for Lymphoma

    Opdivo is under phase II study for the use in the treatment of relapsed or refractory classical Hodgkin’s lymphoma.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.